Log In
Print
BCIQ
Print
Print this Print this
 

quisinostat

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionHistone deacetylase (HDAC) inhibitor
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationCutaneous T cell lymphoma (CTCL)
Indication DetailsTreat cutaneous T cell lymphoma (CTCL)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today